Mirion Technologies, Inc. - 10-Q Summary (Q2 2025)
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2025. Mirion Technologies, Inc. is a global provider of radiation detection, measurement, analysis, and monitoring products and services for medical, nuclear, and defense markets. The company operates through two segments: Medical and Nuclear & Safety.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Total Revenues | $222.9 million | $207.1 million | $424.9 million | $399.7 million |
| Gross Profit | $102.5 million | $97.4 million | $198.6 million | $184.5 million |
| Gross Margin | 46.0% | 47.0% | 46.7% | 46.2% |
| Operating Income | $9.9 million | $2.3 million | $18.6 million | ($2.6 million) |
| Net Income (Attributable to Mirion) | $8.3 million | ($11.7 million) | $8.6 million | ($37.5 million) |
| Diluted EPS | $0.03 | ($0.06) | $0.04 | ($0.19) |
| Operating Cash Flow (YTD) | $48.0 million (vs. $21.2 million YTD 2024) | |||
| Cash & Equivalents | $262.6 million (as of June 30, 2025) | |||
| Total Debt (Principal) | $451.9 million Term Loan + $400.0 million Convertible Notes |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 7.6% QoQ and 6.3% YTD, driven by organic volume growth, price increases, and favorable foreign exchange impacts in both segments.
- Profitability Turnaround: The company returned to profitability, reporting net income of $8.3 million in Q2 2025 compared to a net loss of $11.7 million in Q2 2024. This was significantly aided by a $13.5 million foreign currency gain (vs. a $0.3 million loss in the prior year).
- Debt Restructuring: In May 2025, the company issued $400.0 million of 0.25% Convertible Senior Notes due 2030. Proceeds were used to repay $244.6 million of the term loan principal and extend the maturity date to June 2032. This resulted in a $5.8 million loss on debt extinguishment.
- Segment Performance:
- Medical: Operating income rose to $10.9 million (from $5.0 million) due to reduced amortization and volume growth.
- Nuclear & Safety: Operating income increased to $19.0 million (from $18.5 million), driven by volume and pricing, partially offset by inflation and labor costs.
Guidance, Outlook, and Risks
- Backlog: Total backlog (remaining performance obligations) stands at $819.0 million as of June 30, 2025, up from $811.9 million at year-end 2024.
- Acquisition: On July 31, 2025 (subsequent event), the company signed an agreement to acquire Certrec Corporation for $81.0 million in cash to expand its nuclear regulatory compliance portfolio.
- Key Risks:
- Geopolitical: Exposure to Russia/Ukraine conflict (approx. $122.8 million in Russian-related backlog) and trade tensions with China.
- FX Volatility: Significant impact on results due to European operations; Q2 results included a large unrealized FX gain.
- Interest Rates & Inflation: Rising rates increase debt service costs; inflation impacts material and labor costs, particularly in France.
- Tax Legislation: The "One Big Beautiful Bill Act" signed July 4, 2025, may impact future effective tax rates, though not included in Q2 results.
Investor Verification Checklist
- FX Impact: Verify the sustainability of operating margins excluding the $13.5 million one-time foreign currency gain in Q2.
- Debt Profile: Confirm the impact of the new $400M convertible notes on future interest expense and potential dilution (conversion price ~$23.11).
- Russia Exposure: Assess the risk to the $122.8 million backlog associated with Russian projects and the status of the $17.6 million in net contract assets/receivables.
- Acquisition Integration: Monitor the integration and financial impact of the Certrec Corporation acquisition announced in late July 2025.
- Working Capital: Review the increase in "Costs in excess of billings" ($91.6M) and inventory levels ($145.1M) relative to revenue growth.